Biogen (BIIB) Liabilities and Shareholders Equity (2009 - 2026)

Biogen (BIIB) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $29.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 5.17% year-over-year to $29.5 billion; the TTM figure through Mar 2026 stood at $116.5 billion (up 4.73% YoY), while the FY2025 annual figure was $29.4 billion, up 4.96% from the prior year.
• Liabilities and Shareholders Equity came in at $29.5 billion for Q1 2026 at Biogen, roughly flat from $29.4 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $29.5 billion in Q1 2026, with the low at $23.6 billion in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $26.9 billion, with a median of $26.8 billion recorded in 2023.
• Across the five-year window, Liabilities and Shareholders Equity dropped 1.01% in 2022 and increased 13.43% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $24.6 billion in 2022, then rose by 9.33% to $26.8 billion in 2023, then climbed by 4.49% to $28.0 billion in 2024, then climbed by 4.96% to $29.4 billion in 2025, then grew by 0.15% to $29.5 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $29.5 billion, $29.4 billion, and $29.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.